Treatment Options for Cutaneous Squamous Cell Carcinoma

Diagnosis and Treatment

The American Academy of Dermatology recommends surgical excision with adequate margins as the primary treatment for most cutaneous squamous cell carcinomas, offering the best cure rates and local disease control 1, 2
For low-risk tumors, standard excision with margins of 4 to 6 mm to the mid-dermal fat is recommended 1, 2
For high-risk lesions (>2 cm in diameter or high histological grade), margins of at least 6 mm are necessary to achieve 95% cure rates 1, 2
Mohs micrographic surgery is particularly recommended for high-risk tumors, offering complete histological control of margins 3, 1
Complete surgical excision is essential, as incomplete excision is associated with a poor prognosis 3

Curettage and electrodesiccation may be considered for small, well-differentiated, slow-growing tumors on sun-exposed areas 3, 4
Cryosurgery may be used for selected cases in specialized centers, but is not suitable for locally recurrent disease 3
Radiation therapy alone offers comparable short-term and long-term cure rates to other treatments 3
Radiation therapy is particularly indicated for lesions on the lip, nasal vestibule, and ear, where it can provide the best cosmetic and/or functional result 3, 5

For patients with nodal involvement, regional lymph node dissection is preferred 5, 6
Radiation therapy alone is an alternative when surgery is not initially feasible 5
Parotid involvement is a poor prognostic factor; superficial parotidectomy should be performed if the cancer extends into the parotid parenchyma 5

Postoperative radiation therapy is recommended in cases of significant perineural invasion, positive margins after surgery, or nodal involvement in the head and neck region 5
Concurrent chemoradiotherapy may be considered for high-risk tumors 5

Cetuximab (epidermal growth factor receptor inhibitor) is indicated for the treatment of locally or regionally advanced cutaneous squamous cell carcinoma of the head and neck, in combination with radiation therapy or chemotherapy 5

Early detection and treatment improve survival in patients with recurrent disease 3
95% of local recurrences and 95% of metastases are detected within 5 years 3
A 5-year follow-up is recommended for patients with high-risk tumors 3
Patients should be trained in self-examination whenever possible 3

Immunocompromised patients, including solid organ transplant recipients, have a 2- to 3-fold increased risk of metastasis 7
A multidisciplinary approach is strongly encouraged for patients with advanced or metastatic disease 3, 7
For immunocompromised patients with high-risk or metastatic tumors, reduction of immunosuppressive agent doses may be considered 7